| Bioactivity | Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive c-MET inhibitor, with an IC50 of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases). Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research[1]. |
| Target | IC50: 0.93 nM (c-MET) |
| Name | Zgwatinib |
| CAS | 1268264-10-3 |
| Formula | C22H22F3N5O2 |
| Molar Mass | 445.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang, H, et al. SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET-Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 350(1), 36–45. |
Zgwatinib
CAS: 1268264-10-3 F: C22H22F3N5O2 W: 445.44
Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive c-MET inhibitor, with an IC50 of 0.93 nM against c-MET,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.